Rani Therapeutics Holdings Inc. Class A Common Stock (RANI)

FairStock Score: 38/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with owner earnings and a margin of safety. Rani Therapeutics is a clinical-stage biotherapeutics company with a drug-agnostic oral delivery platform, RaniPill. The reported numbers show a business still far from profitability. In FY2025, revenue was $1.6 million and net income was -$29.7 million, or -$0.45 per diluted share. In FY2024, revenue was $1.0 million and net loss was -$30.0 million. In FY2023, net loss was -$34.0 million with revenue not applicable. For fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $1.7 million and net loss was -$7.4 million, a -432.73% margin. Trailing free cash flow is -$20.3 million, a FairStock-calculated FCF yield of -14.8%. These are not the marks of a mature business; they are the marks of a cash-consuming experiment. The RaniPill may have promise as an alternative to injections, but promise is not a moat. There is no approved product mentioned, so pricing power and recurring earnings are unproven. At the 2026-10-13 close of $0.73, market cap is $137.2 million. FairStock calculations show P/E -5.64 and P/B 2.09; ROE is -172.15% and ROCE is -52.99%. The low D/E of 0.07 and Altman Z-score of 3.47 are relative positives, but Piotroski is only 3/9 and the Lynch category is none because of losses in each of the last four years. I see a speculative pipeline, not a bargain. I would need evidence of clinical success, revenue scale, and shrinking cash burn before the current price could be justified by business fundamentals.

In plain English: Rani Therapeutics is a small healthcare company testing a pill that could let patients take medicines now given by injection. The business is not yet profitable: it has very little revenue and loses millions of dollars each quarter while spending cash. At $0.73 a share, the price is not supported by current profits; it mainly reflects hopes for its experimental pill.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer